Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.
The successful management of obesity requires a long-term approach that is tailored to an individual's lifestyle and needs. Initial treatment should focus on lifestyle modifications-dietary interventions and increased physical activity-with behavioral modification strategies used adjunctively. Several antiobesity drugs are approved by the Food and Drug Administration for use in obese patients, as well as in overweight individuals with at least one obesity-related comorbidity. Most are approved only for short-term weight loss, but sibutramine and orlistat are approved for long-term weight loss and maintenance. In addition to weight reduction, in clinical trials these drugs provided beneficial actions on several cardiovascular risk factors. Several other drugs currently approved for other uses show promise in their ability to cause weight loss. Surgical options should be reserved for severely obese patients with significant medical comorbidities or physical conditions.
Fujioka
Ken
K
Nutrition and Metabolic Research Center, Scripps Clinic, San Diego, California 92130, USA. kfujioka@scrippsclinic.com
D019440:Anti-Obesity Agents / Q000627:therapeutic use; D001067:Appetite Depressants / Q000627:therapeutic use; D001521:Behavior Therapy; D002908:Chronic Disease; D004032:Diet; D015444:Exercise; D015390:Gastric Bypass; D015391:Gastroplasty; D006801:Humans; D009765:Obesity / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*
D019440:Anti-Obesity Agents; D001067:Appetite Depressants